Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharmacol ; 969: 176454, 2024 Apr 15.
Article in English | MEDLINE | ID: mdl-38417607

ABSTRACT

Estrogen hormone replacement therapy (EHRT), improving women's life quality at menopause, reduces anxiety and depression symptoms associated with ovarian hormonal decline. However, its potential adverse effects, like thromboembolism and cancer risk, limit its use. Prolame is a synthetic 17ß-amino estrogen with antithrombotic actions that exerts anxiolytic- and antidepressant-like effects on young adult ovariectomized female rats. It is unknown if prolame's effects may be observed in age and endocrine conditions emulating menopause. This study aimed to identify the antidepressant- and anxiolytic-like effects of prolame and E2 (used as a reference estrogen treatment) in middle-aged female rats coursing with irregular cycles, in two different conditions: ovariectomized or gonadally intact. Results were compared with those from young adult ovariectomized rats. Prolame (60 or 120 µg/kg), 17ß-estradiol (E2, 40 or 80 µg/kg), or vehicle were chronically administered, and their effects were evaluated in the elevated plus-maze, defensive burying behavior test, open field test, and forced swimming test. Uterotrophic actions were estimated by uterine weight related to body weight. Prolame and E2 produced robust anxiolytic- and antidepressant-like effects in young adult ovariectomized rats, but these effects were absent in gonadally intact middle-aged rats. Interestingly, only prolame induced anxiolytic- and antidepressant-like effects in middle-aged ovariectomized rats. Uterotrophic effects of prolame were weaker than E2 effects, notably in middle-aged females. Altogether, present data support the notion that prolame has the potential to be considered an EHRT with relevant psychoactive actions and with apparently lower adverse-side effects, especially in middle-aged populations.


Subject(s)
Anti-Anxiety Agents , Estrenes , Humans , Rats , Female , Animals , Middle Aged , Anti-Anxiety Agents/pharmacology , Anti-Anxiety Agents/therapeutic use , Rats, Wistar , Estradiol/pharmacology , Estradiol/therapeutic use , Estrogens/pharmacology , Estrogens/therapeutic use , Antidepressive Agents/pharmacology , Antidepressive Agents/therapeutic use , Ovariectomy/adverse effects
2.
Article in English | MEDLINE | ID: mdl-26239795

ABSTRACT

Estrogens of clinical use produce consistent antidepressant- and anxiolytic-like effects in animal models of menopause. Regulation of the hypothalamic-pituitary-adrenal (HPA) or stress axis, has been proposed as a pathway through which estrogens improve affective-like behaviors. Anticoagulant 17ß-aminoestrogens (17ß-AEs) butolame and pentolame mimic some effects of estradiol (E2), i.e., on female rodent sexual behavior, with opposite actions on coagulation. However, their psychoactive actions have not been explored. On the basis of similitude with E2's effects, we hypothesized that these 17ß-AEs would induce anxiolytic- and antidepressant-like effects, which would be reflected in a reduction of activity in the HPA axis. In ovariectomized female rats, chronic treatment with prolame (60 µg/kg), butolame (65 µg/kg) and pentolame (70 µg/kg) reduced anxiety-like behavior in the elevated plus maze (evidenced by an increase in time in open arms, E2 (40 µg/kg) +176%; prolame +201%; butolame, +237%; and pentolame +295%, in comparison to the control vehicle group 100%). Pentolame also decreased significantly anxiety-like behavior in the burying behavior test. Prolame and E2 produced a significantly antidepressant-like action, which was not induced by butolame and pentolame. Behavioral effects of 17ß-AEs (and E2) on anxiety and depression did not follow the same pattern than corticosterone or E2 levels; they also were associated to changes in locomotor activity, evaluated by the open field test. These results constitute the first evidence of specific and selective actions of butolame and pentolame as anxiolytics for females with a hypoestrogenic condition. Results also confirm the potential of prolame as an antidepressant steroid with equivalent actions to E2. Psychoactive properties of 17ß-AEs in combinations with reduced adverse effects on coagulation, suggest that 17ß-AEs may be a good alternative replacement therapy for women with symptoms associated with menopause.


Subject(s)
Amino Alcohols/pharmacology , Anxiety Disorders/drug therapy , Depressive Disorder/drug therapy , Estrenes/pharmacology , Psychotropic Drugs/pharmacology , Amino Alcohols/blood , Amino Alcohols/chemistry , Animals , Anticoagulants/blood , Anticoagulants/chemistry , Anticoagulants/pharmacology , Anxiety Disorders/physiopathology , Depressive Disorder/physiopathology , Disease Models, Animal , Dose-Response Relationship, Drug , Estradiol/blood , Estradiol/chemistry , Estradiol/pharmacology , Estrenes/blood , Estrenes/chemistry , Exploratory Behavior/drug effects , Female , Motor Activity/drug effects , Ovariectomy , Psychotropic Drugs/blood , Psychotropic Drugs/chemistry , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...